Prelude Therapeutics (PRLD) Other Accumulated Expenses (2019 - 2026)

Prelude Therapeutics has disclosed Other Accumulated Expenses across 8 years of filings, most recently posting $911000.0 for Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $911000.0, up 30.89% year-over-year; the trailing twelve-month figure through Mar 2026 was $911000.0 (up 30.89% YoY), and the FY2025 annual result was $965000.0, up 25.16% from the prior year.
• Other Accumulated Expenses came in at $911000.0 for Q1 2026 at Prelude Therapeutics, down from $965000.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $965000.0 in Q4 2025 to a low of $175000.0 in Q3 2022.
• The 5-year median for Other Accumulated Expenses is $801000.0 (2024), against an average of $707411.8.
• Peak annual rise in Other Accumulated Expenses reached 1164.29% in 2022, while the deepest fall reached 69.3% in 2022.
• Prelude Therapeutics' Other Accumulated Expenses stood at $524000.0 in 2022, then jumped by 80.34% to $945000.0 in 2023, then dropped by 18.41% to $771000.0 in 2024, then advanced by 25.16% to $965000.0 in 2025, then retreated by 5.6% to $911000.0 in 2026.
• The last three Other Accumulated Expenses figures came in at $911000.0 (Q1 2026), $965000.0 (Q4 2025), and $963000.0 (Q3 2025), per Business Quant data.